시장보고서
상품코드
1480421

세계의 펩타이드 치료제 시장

Peptide Therapeutics

발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 192 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

펩타이드 치료제 세계 시장은 2030년까지 563억 달러에 달할 전망

2023년에 421억 달러로 추정되는 펩타이드 치료제 세계 시장은 2023년부터 2030년까지 4.3%의 CAGR로 성장하여 2030년에는 563억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 혁신적인 펩타이드 치료제는 CAGR 2.8%를 기록하고, 분석기간 종료까지 299억 달러에 달할 것으로 예측됩니다. 제네릭 펩타이드 치료제 분야의 성장은 향후 7년간 CAGR이 6.2%로 예측됩니다.

미국 시장은 112억 달러, 중국은 CAGR 7.3%로 성장할 것으로 예측

미국의 펩타이드 치료제 시장은 2023년에는 112억 달러에 달할 것으로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 124억 달러의 시장 규모에 달할 것으로 예측되며, 분석기간 2023년에서 2030년 CAGR은 7.3%입니다. 기타 주목할 만한 지역 시장으로는 일본과 캐나다가 있고, 각각 2023년부터 2030년까지 1.5%와 4.4%의 성장이 예측됩니다. 유럽에서는 독일이 CAGR 1.8%로 성장할 것으로 예측됩니다.

2024년에 새롭게 선보이는 흥미로운 보고서 기능 소개

인플루언서 참여 통계에 대한 풀 액세스

디지털 아카이브와 "MarketGlass" 조사 플랫폼에 무료로 액세스할 수 있습니다. 당사의 독자적인 MarketGlass 플랫폼은 전 세계 전문가들의 창의성과 시장 지식을 통합적이고 협력적으로 발휘할 수 있도록 지원합니다. 당사의 최첨단 도구는 시장 진입자의 프라이버시와 신원을 보호하면서 세계적 수준의 시장 전망을 제공합니다. 보고서의 수치, 통계 및 시장 설명은 이 분야의 전문가와 영향력 있는 사람들이 공유한 완전히 선별된 인사이트를 기반으로 합니다.

실시간 데이터 시뮬레이터 도구와 맞춤형 보고서 작성 기능을 갖춘 인터랙티브 설문 조사에 참여할 수 있습니다.

기업 간 스마트한 의견 교환을 위한 피어 협업 인터랙티브 플랫폼에 대한 풀 클라이언트 액세스

1년간 무료 보고서 업데이트

주요 기업의 세계 시장 점유율을 포함한 경쟁 커버리지

여러 지역에 걸친 기업의 시장 입지 분석(호조/활발/틈새/마이너)

전문가/인플루언서 인터뷰, 팟캐스트, 언론 발표, 이벤트 기조연설 유튜브 동영상에 대한 접근성

2024년 세계 경제에 대한 기대

통화 긴축과 이에 따른 금리 상승으로 인한 지정학적, 경제적 불안정성이 2024년 격동적인 상황을 만들어 낼 것으로 보입니다. 중동의 적대 행위와 점점 더 잦아지는 기후 재해 등 여러 요인들이 회복의 길에 계속 압력을 가할 것으로 예상됩니다. 위험요인이 있는 반면, 디플레이션 조짐이 강해지고, 완고한 인플레이션에 대한 불안감이 완화되고, 공급망이 정상화되고, 에너지 비용 변동에도 불구하고 물가가 완만하게 상승하는 등 몇 가지 긍정적인 요인도 나타나고 있습니다. 인도와 미국을 비롯한 G21 국가들의 선거는 자본 흐름과 투자 전략에 영향을 미칠 수 있습니다. 인도가 글로벌 투자처로 주목받고 있는 가운데, 미국에 기반을 둔 하이테크 기업들은 역동적인 인재와 자본 생태계에 힘입어 계속 우위를 점할 것으로 보입니다. 실리콘밸리를 비롯한 하이테크 기회는 국내 경제가 둔화되긴 했지만 여전히 견고하고 규제 환경이 잘 정비되어 있어 높은 성장 잠재력을 추구하는 투자자들에게 여전히 매력적일 것으로 보입니다. 유럽은 긴축정책과 경기침체 리스크와의 싸움이 계속되고 있으며, 영국은 2024년 경기침체 리스크가 가장 높은 국가로 가장 어려운 전망을 보이고 있습니다. 중국은 정부 지출과 개인 소비 개선에 힘입어 성장세를 이어갈 것으로 예상되는 와일드카드가 될 것입니다. 불안정한 환경은 투자자와 기업 모두에게 기회와 도전을 동시에 가져다 줄 것으로 보입니다. 변동성을 성장의 촉매제로 받아들이고, 민첩한 투자 판단과 전략적 선견지명이 생존을 위한 핵심 요소로 작용할 것입니다.

조사 대상 기업 사례(총 33건)

  • AbbVie, Inc.
  • Advanced Accelerator Applications SA
  • Akashi Therapeutics, Inc.
  • Amgen, Inc.
  • Anthera Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Bachem AG
  • Bristol-Myers Squibb Company
  • Cardiorentis AG
  • Corden Pharma International GmbH
  • Debiopharm Group
  • Derma Sciences, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Hanmi Pharmaceutical Co., Ltd.
  • Insmed, Inc.
  • Ipsen Group
  • Johnson & Johnson
  • Lonza Group AG
  • Mallinckrodt PLC
  • Merck & Co., Inc.
  • MolMed S.p.A.
  • Novartis AG
  • Novo Nordisk A/S
  • Nymox Pharmaceutical Corporation
  • PAR Pharmaceutical Companies, Inc.
  • PeptiDream Inc.
  • Pfizer, Inc.
  • PolyPeptide Group
  • Radius Health, Inc.
  • Repligen Corporation
  • Sanofi SA
  • SciClone Pharmaceuticals Holding Limited.
  • Shire PLC
  • Takeda Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • The Medicines Company
  • X-GEN Pharmaceuticals, Inc.
  • Zealand Pharma A/S
  • Zydus Cadila

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 성장 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 24.05.22

Global Peptide Therapeutics Market to Reach $56.3 Billion by 2030

The global market for Peptide Therapeutics estimated at US$42.1 Billion in the year 2023, is expected to reach US$56.3 Billion by 2030, growing at a CAGR of 4.3% over the period 2023-2030. Innovative Peptide Therapeutics, one of the segments analyzed in the report, is expected to record 2.8% CAGR and reach US$29.9 Billion by the end of the analysis period. Growth in the Generic Peptide Therapeutics segment is estimated at 6.2% CAGR for the next 7-year period.

The U.S. Market is Estimated at $11.2 Billion, While China is Forecast to Grow at 7.3% CAGR

The Peptide Therapeutics market in the U.S. is estimated at US$11.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$12.4 Billion by the year 2030 trailing a CAGR of 7.3% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.5% and 4.4% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Introducing Our Exciting New Report Features for 2024

Full access to influencer engagement stats

Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.

Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities

Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas

Complimentary report updates for one year

Competitor coverage with global market shares of major players

Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies

Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes

What to Expect from the Global Economy in 2024

Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 33 Featured) -

  • AbbVie, Inc.
  • Advanced Accelerator Applications SA
  • Akashi Therapeutics, Inc.
  • Amgen, Inc.
  • Anthera Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Bachem AG
  • Bristol-Myers Squibb Company
  • Cardiorentis AG
  • Corden Pharma International GmbH
  • Debiopharm Group
  • Derma Sciences, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Hanmi Pharmaceutical Co., Ltd.
  • Insmed, Inc.
  • Ipsen Group
  • Johnson & Johnson
  • Lonza Group AG
  • Mallinckrodt PLC
  • Merck & Co., Inc.
  • MolMed S.p.A.
  • Novartis AG
  • Novo Nordisk A/S
  • Nymox Pharmaceutical Corporation
  • PAR Pharmaceutical Companies, Inc.
  • PeptiDream Inc.
  • Pfizer, Inc.
  • PolyPeptide Group
  • Radius Health, Inc.
  • Repligen Corporation
  • Sanofi SA
  • SciClone Pharmaceuticals Holding Limited.
  • Shire PLC
  • Takeda Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • The Medicines Company
  • X-GEN Pharmaceuticals, Inc.
  • Zealand Pharma A/S
  • Zydus Cadila

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Peptide Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Peptide Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Peptide Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Peptide Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Innovative by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Innovative by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Innovative by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Generic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Cardiovascular Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Peptide Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Liquid Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Liquid Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Liquid Phase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Solid Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Solid Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Solid Phase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hybrid Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Hybrid Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Hybrid Phase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Metabolic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Metabolic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Metabolic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Anti-Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Anti-Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Anti-Infection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Respiratory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Peptide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2024 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2014, 2024 & 2030
  • JAPAN
    • Peptide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2024 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2014, 2024 & 2030
  • CHINA
    • Peptide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2024 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: China 16-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: China 16-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2014, 2024 & 2030
  • EUROPE
    • Peptide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Peptide Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Peptide Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Peptide Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2014, 2024 & 2030
  • FRANCE
    • Peptide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2024 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: France 16-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: France 16-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2014, 2024 & 2030
  • GERMANY
    • Peptide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2024 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2024 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Peptide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2024 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2024 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2024 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2024 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Peptide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Peptide Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Peptide Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Peptide Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2024 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Peptide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2024 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2014, 2024 & 2030
  • INDIA
    • Peptide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: India 16-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2024 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: India 16-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: India 16-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2024 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2024 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Peptide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Peptide Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Peptide Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Peptide Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2024 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2024 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2024 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2024 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2024 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Peptide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Peptide Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Peptide Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Peptide Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2024 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2024 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2024 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2024 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2024 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2024 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2014, 2024 & 2030
  • AFRICA
    • Peptide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Peptide Therapeutics by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Peptide Therapeutics by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Peptide Therapeutics by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2024 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Peptide Therapeutics by Application - Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Peptide Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Peptide Therapeutics by Synthesis Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Peptide Therapeutics by Synthesis Technology - Percentage Breakdown of Value Sales for Liquid Phase, Solid Phase and Hybrid Phase for the Years 2014, 2024 & 2030

IV. COMPETITION

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제